Cellesce, has announced a collaboration with Repositive, which has developed the Cancer Models product, a searchable web-based platform, that connects cancer researchers to the models and services they need to drive research.

The new partnership will expand the number of Repositive’s partners on Cancer Models to 12. Repositive’s integrated web-based solution, enables researchers to find cancer models derived from human tumours with many from commercial sources now searchable in one place.

Researchers worldwide can use Repositive’s platform to compare standardised molecular features, create collections and share with their team. Cellesce will keep control of data access, learn which models are most popular, and connect with new and existing customers.

Cellesce uses its proprietary bioprocessing technology to consistently expand tumour-derived organoid lines that originate from patient tissue. These organoids accurately recapitulate disease-causing genetic mutations and are produced in sufficient consistency, quality and quantity to support drug applications for compound screening.

This collaboration will provide novel and more complete research solutions to support commercial and academic partners as they undertake basic cancer research and pursue drug discovery programmes using tumour-derived organoids.

Dr Mark Treherne, Chief Executive of Cellesce, commented: “By partnering to provide an integrated drug discovery solution, Cellesce and Repositive are now in a position to provide a more comprehensive package to academic and commercial researchers working on cancer to find the most relevant organoids for their needs. This strategic partnership further underscores the value of providing organoids at scale and highlights the impact our models are having on the global research community.”

“By working with Cellesce, we’re making it easier for oncology researchers and data providers to collaborate and speed up the development of new treatments. Organoids expanded by Cellesce will further enable and expand our web-based solution.” said Dr Fiona Nielsen, Co-Founder and Chief Executive Officer of Repositive.

This new collaboration was announced at EORTC-NCI-AACR 2018, which took place at the Dublin Convention Centre on Wednesday 14th November during which Repositive hosted its Pre-Clinical Oncology Showcase. Dr Mark Treherne, Cellesce CEO was one of the presenters.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *